Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 196.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 6.00 (3.158%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 196.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

Thu, 13th Oct 2022 21:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Bidstack Group PLC - London-based in-game advertising platform - Appoints Camila Franklin as chief operating officer. She is replacing Lisa Hau who will move on to be the company's chief strategy officer. Franklin was previously COO at the gaming monetisation platform AdColony Inc.

----------

Hamak Gold Ltd - British Virgin Islands-based gold exploration firm focused on Liberia - Signs a contract with Cestos Drilling Liberia for an initial drilling programme to identify the depth and width extensions of significant gold mineralization. "We will shortly commence a drilling programme to test the width and depth extensions of the significant gold mineralization identified by soil and channel sampling over the Ziatoyah outcrop in our Nimba licence. We are pleased to be working with Cestos who have agreed to accept equity for the majority of their drilling services, showing their confidence in our programme and helping to conserve cash for the company in these challenging equity markets," Executive Director Karl Smithson comments.

----------

Amigo Holdings PLC - Bournemouth, England-based guarantor loan provider - Gets approval from the Financial Conduct Authority to return to lending with immediate effect. Notes that this is under "certain agreed conditions." Under the terms, it will undertake further customer outcomes testing, led by a third party, during the initial two-month pilot lending phase and a required period for assessment. If the FCA is satisfied with the outcome of this pilot phase, it will still be limited to a maximum of GBP35 million cumulative net originations until a further minimum GBP15 million scheme contribution from the proposed capital raise is paid into the scheme fund, it says.

----------

Arbuthnot Banking Group PLC - London-based bank - Notes its subsidiary, Arbuthnot Latham & Co Ltd, completed the sale of its long leasehold West End office property, 20 King Street, following the satisfaction of conditions.

----------

Fintel PLC - Huddersfield, England-based technology and support for retail financial services sector - Expands its strategic distribution partnership with Schroders PLC. Says Schroders will join Fintel's Risk Controlled investment solution. "Schroders and Fintel have worked closely together for a number of years and I am delighted that they have chosen to further strengthen this relationship by joining our Risk Controlled range. Fintel exists to help the market operate more effectively and with the continued success of the Managed Distribution and Risk Controlled we continue to deliver the technology and insight-led solutions the industry needs to ensure better consumer outcomes," Joint Chief Executive Matt Timmins comments.

----------

Minoan Group PLC - Surrey-based Greek hotel investor - Appoints Marco Nijhof to its board effective immediately. Says he is a board-level executive within the international luxury hotel and retail hospitality industry. "The appointment of Marco today is one of the final keys to reaching the commercialisation stages of the project. His experience in developing, commercialising and operating world-class tourism and other businesses will be crucial in the coming months as we near crystallisation of the project with the attendant increase in shareholder value," Chair George Mergos comments.

----------

Silverwood Brands PLC - London-based investing company targeting food, organic food, wellness, lifestyle and leisure sectors - Raises gross proceeds of GBP2.0 million through a subscription for new ordinary shares at an issue price of 40 pence per share. Records total income of GBP831,415 in the year to August 31. Net loss total GBP299,103.

----------

Artemis Resources Ltd - Perth-based miner with gold, copper and cobalt projects in Australia - Says the Greater Carlow project is a "high-grade gold copper-cobalt project primed for further growth". Says its resource compares very favourably to other gold mining projects on a grade equivalent basis. "What we have now established at the Greater Carlow project is a robust, credible, high-grade multi-metal resource from which our exploration team can now seek to continue to grow via drilling. The next phase at Greater Carlow is to drill and add more high-grade tonnes to the open pit and underground resources, including the high-grade Keel Zone which is not included in this resource statement," Executive Director Alastair Clayton comments.

----------

Cobra Resources PLC - Wudinna gold project in South Australia - Starts reverse circulation drilling at the Clarke prospect of its Wudinna gold project. This drilling will inform an updated gold mineral resource estimate and a maiden rare earth mineral resource estimate, it says.

----------

Firing Strategic Minerals PLC - operator of Atex dual lithium-tantalum project in Ivory Coast - Drills a total of 19 holes and completes 3,039 meters of drilling. It intersects pegmatite in all 19 drill holes. "I am pleased to provide our next update regarding our phase 1 core drilling programme, which has been completed successfully ... Lithium mineralisation was visually observed in eighteen out of the 19 holes, and we are now eagerly awaiting the assay results, the first of which should arrive during the fourth quarter of 2022," Chief Executive Yuval Cohen says.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Proposes a private placement to raise around EUR8 million through an accelerated book building. Plans to use the net proceeds of the placing would be used for the acceleration of the bexmarilimab clinical development programme and manufacturing. Total cash and cash equivalents held by the company as of June 30 amounted to EUR9.9 million.

----------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - Starts direct lithium extraction process work at its sustainable lithium projects in Chile. "We are delighted to move forward our process test-work with SunResin on multiple fronts including trials on brine from the sub-surface aquifers of our Laguna Verde and Francisco Basin projects, ordering of a DLE demo unit which will arrive in Chile this month and receiving a proposal for the DLE unit for a pilot plant that will produce battery grade lithium carbonate and lithium hydroxide for customer testing and verification," Chief Executive Aldo Boitano comments.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 Dec 2023 11:01

Faron publishes cancer immunotherapy study findings

(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.

Read more
6 Nov 2023 11:03

IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.

Read more
6 Nov 2023 10:31

Faron reveals details of next stage of bexmarilimab study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).

Read more
30 Oct 2023 15:56

TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
11 Oct 2023 14:53

Faron Pharmaceuticals upbeat on latest data in blood cancer trials

(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.

Read more
11 Oct 2023 14:01

IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Says eight of eleven patients were complete responders or complete responders with incomplete blood recovery. Adds Bexmarilimab continues to be well-tolerated at all tested dose levels, as no dose-limiting toxicity has been observed.

Read more
21 Sep 2023 14:45

Faron Pharmaceuticals names interim chief medical officer

(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical officer on Thursday, with the transition becoming effective on 22 September, with Dr Berns operating from the UK.

Read more
21 Sep 2023 12:12

TRADING UPDATES: Faron appoints Birge Berns as interim medical officer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Sep 2023 15:46

UK shareholder meetings calendar - next 7 days

Monday 18 September 
Baillie Gifford US Growth Trust PLCAGM
Inteliqo LtdAGM
LendInvest PLCAGM
Rosslyn Data Technologies PLCGM re fundraise
Tuesday 19 September 
Africa Opportunity Fund LtdAGM
Aston Martin Lagonda Global Holdings PLCGM re supply arrangement with Lucid Group Inc
Augmentum Fintech PLCAGM
Beacon Rise Holdings PLCAGM
Begbies Traynor Group PLCAGM
Chill Brands Group PLCAGM
DP Aircraft I LtdAGM
Great Southern Copper PLCAGM
Manolete Partners PLCAGM
Moonpig Group PLCAGM
Oxford Instruments PLCAGM
ProCook Group PLCAGM
SRT Marine Systems PLCAGM
Unicorn Mineral Resources PLCAGM
Wednesday 20 September 
Accsys Technologies PLCAGM
Frasers Group PLCAGM
Games Workshop Group PLCAGM
Hidong Estate PLCAGM
IG Group Holdings PLCAGM
Ilika PLCAGM
Nippon Active Value Fund PLCGM re assets rollover
Quiz PLCAGM
Seed Innovations LtdAGM
STS Global Income & Growth Trust PLCAGM
Thursday 21 September 
Ascent Resources PLCGM re audited annual accounts
Intercede Group PLCAGM
Kore Potash PLCGM re capital raise
Liontrust Asset Management PLCAGM
Mercia Asset Management PLCAGM
Molecular Energies PLCAGM
Oberon Investments Group PLCAGM
Pelatro PLCGM re AIM cancellation
Sosandar PLCAGM
Thruvision Group PLCAGM
Trakm8 Holdings PLCAGM
Van Elle Holdings PLCAGM
Friday 22 September 
Argos Resources LtdGM re members voluntary liquidation
B&M European Value Retail SAGM re appointing Lasry as director
Faron Pharmaceuticals LtdEGM re election of new board members
Stranger Holdings PLCAGM
SysGroup PLCAGM
TI Fluid Systems PLCGM re waiver resolution
Odyssean Investment Trust PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
29 Aug 2023 10:23

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
29 Aug 2023 10:15

Faron shares surge on FDA drug designation; loss widens on costs

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & Drug Administration orphan drug designation for Bexmarilimab.

Read more
22 Aug 2023 15:46

UK earnings, trading statements calendar - next 7 days

Wednesday 23 August 
Angling Direct PLCTrading Statement
Costain Group PLCHalf Year Results
Thursday 24 August 
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
James Cropper PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Princess Private Equity Holding LtdHalf Year Results
Redcentric PLCFull Year Results
South32 LtdFull Year Results
Tribal Group PLCHalf Year Results
Friday 25 August 
no events scheduled 
Monday 28 August 
no events scheduled 
Tuesday 29 August 
Amaroq Minerals LtdHalf Year Results
Bunzl PLCHalf Year Results
Dalata Hotel Group PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
PureTech Health PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jul 2023 10:27

Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data.

Read more
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.